logo-loader
viewHumanigen, Inc.

Humanigen's new data show increase in mice survival with lenzilumab

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the company a new study evaluating lenzilumab, its flagship therapy, shows it improves the effectiveness of CAR-T, a new approach to cancer therapy involving altered T cells.

Durrant says the Burlingame, California, company is looking toward clinical studies with human patients before the end of the year.

Quick facts: Humanigen, Inc.

Price: 0.51 USD

OTCQB:HGEN
Market: OTCQB
Market Cap: $57.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Argo Blockchain CEO 'super optimistic on 2020' as it...

Argo Blockchain PLC's (LON:ARB) Peter Wall chats to Proactive London's Andrew Scott soon after assuming the role of CEO. He says they're ahead of schedule to reach their goal of 17,000 installed machines by the end of the first quarter of this year. ''2020 is really about optimising what...

3 hours, 26 minutes ago

2 min read